Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. [electronic resource]
Producer: 20190111Description: 1095-1104 p. digitalISSN:- 1029-2403
- Aged
- Aged, 80 and over
- Anemia -- epidemiology
- Antimetabolites, Antineoplastic -- therapeutic use
- Azacitidine -- therapeutic use
- Blood Transfusion -- methods
- Chromosome Deletion
- Chromosomes, Human, Pair 5 -- genetics
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Myelodysplastic Syndromes -- genetics
- Palliative Care
- Prognosis
- Prospective Studies
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.